COAG Stock — Hemab Therapeutics Holdings Inc.: Cash, EV, Pipeline

What they do

Hemab Therapeutics Holdings, Inc. (the “Company”) is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience.

Source: 10-Q FY2026 via SEC EDGAR

Share price

$49.02

Market cap

$2,289.8M

Cash

$457.5M

Enterprise value

$1,832.3M

Balance sheet

Cash	$457.5M
Debt	$0.0M
Net cash	$457.5M
Enterprise value	$1,832.3M
Basic shares	46.7M shares
Fully diluted shares	51.8M shares
Fully diluted market cap	$2,538.2M
Cash per share	$9.79
Quarterly burn	$22.6M
Cash runway	20.2 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

46.7M

Pre-funded warrants

0.0M

Options

0.3M

RSUs

0.0M

Warrants

4.3M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.4M

FDSO

51.8M

Cap table as of 2026-06-30.

Price history

Loading COAG daily closes…

Loading price history…

Next catalyst

HMB-003 · Jun 11 - Jul 23 in 7 mo · Phase 1 · Healthy Adult Participants

Recently reported

Sutacimig Phase 2 Mixed · 2026-11-04

HMB-001-201 · congenital factor vii deficiency

Primary: Pharmacokinetic and pharmacodynamic results (prothrombin time and endogenous FVII(a) accumulation) after a single subcutaneous dose in the single-ascending-dose cohort — Both participants had a baseline prothrombin time of ≥180 seconds, which shortened by more than 50% following dosing; in the participant with PK/PD data available to date, sutacimig produced sustained accumulation (~5x) of endogenous total FVII(a), with exposure maintained through Day 22

· 2 participants with severe congenital FVIID had received a single subcutaneous dose as of July 24, 2026

· Phase 2b study HMB-001-201 (NCT07347249), conducted at a single site in the UK

· Abstract Number: abs26-10755, to be presented at ASH on December 14, 2026

Safety: Adverse events were low grade and assessed as not related to treatment

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jun 11 - Jul 23 in 7 mo	HMB-003	Phase 1	Healthy Adult Participants	—
Aug 12 - Sep 23 in 9 mo	HMB-002 (Part A)	Phase 1/2	Von Willebrand Disease (VWD); Von Willebrand Disease (VWD), Type 1; Von Willebrand Disease (VWD), Type 2	—
Sep 12 - Oct 24 in 10 mo	HMB-001	Phase 1/2	Glanzmann Thrombasthenia	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

sutacimig

Phase 1 · Active Modality: bispecific antibody

Aliases HMB-001

Target TLT-1 / Factor VII

Partnerships Novo Nordisk: license to TLT-1/FVII bispecific antibody IP; Genmab: DuoBody platform license

Indications

Glanzmann thrombasthenia (prophylaxis) (Phase 1)
Factor VII deficiency (prophylaxis) (Phase 2)

Status note Lead asset. Phase 1/2 in Glanzmann thrombasthenia; Phase 2 in Factor VII deficiency. July 2026: sustained prophylactic effect in long-term extension of Phase 2 GT trial; identified 0.2 mg/kg once-weekly dose for planned Phase 3, endorsed by FDA.

HMB-002

Phase 1 · Active Modality: monovalent antibody

Indications

Von Willebrand Disease (subcutaneous prophylaxis) (Phase 1)

Status note Second clinical-stage asset; Phase 1/2 in subcutaneous prophylactic treatment of Von Willebrand Disease.

HMB-003

Preclinical · Active

Target plasmin

Indications

coagulation disorders (Preclinical)

Status note Preclinical program in coagulation disorders; no further detail in filing excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Sutacimig
Lead indication	Congenital Factor VII Deficiency
Lead phase	Phase 2
Active trials	5
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07347249	Phase 2	Recruiting	Sponsor	Hemab ApS	—	Congenital Factor VII Deficiency	—
NCT06754852	Phase 1/2	Recruiting	Sponsor	Hemab ApS	—	Von Willebrand Disease (VWD); Von Willebrand Disease (VWD), Type 1; Von Willebrand Disease (VWD), Type 2	—
NCT06211634	Phase 1/2	Active, not recruiting	Sponsor	Hemab ApS	—	Glanzmann Thrombasthenia	—
NCT07798505	Phase 1	Recruiting	Sponsor	Hemab ApS	—	Healthy Adult Participants	—
NCT06610201	Not disclosed	Recruiting	Sponsor	Hemab ApS	—	Von Willebrand Disease (VWD); Von Willebrand Disease (VWD), Type 1; Von Willebrand Disease (VWD), Type 2	—
NCT04398628	Not disclosed	Recruiting	Collaborator	American Thrombosis and Hemostasis Network	NVO, PFE, SNY	Hematologic Disorder; Bleeding Disorder; Connective Tissue Disorder	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for Hemab ApS on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RA Capital Management	7,808,627	+7,808,627	2.49%	2026-08-14
Avoro Capital Advisors	1,925,150	+1,925,150	0.63%	2026-08-14
Deerfield Management	275,000	+275,000	0.11%	2026-08-14
Braidwell LP	160,000	+160,000	0.22%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

COAG — Hemab Therapeutics Holdings Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

COAG — Hemab Therapeutics Holdings Inc.